EE50 Olaparib As Maintenance Therapy for Women with Ovarian Cancer and Homologous Recombination Deficiency in Brazil: What Clinical and Cost Data Have Highest Impact on Cost-Effectiveness Analysis?

Abstract

In Brazil, it is estimated that OC(ovarian cancer) impacts 7/100,000 habitants every year. Until recently, platinum-based therapies were considered standards of care and few innovations could significantly reduce disease progression or survival status(PFS). PARPi(Poly ADP-ribose polymerase inhibitor), such as olaparib, has shown to improve PFS by 51% compared to placebo in first-line maintenance scenario. This result was significantly better in homologous-recombination deficiency(HRD+). New oncology drugs require significant resource allocation, so we assessed which parameters have highest impact on cost-effectiveness analysis(CEA) of olaparib as maintenance therapy for women with HRD+OC, in the Brazilian private health care system.